The concept of superdonor and other possible factors for the effectiveness of fecal microbiota transplantation

Authors

  • S.M. Tkach Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
  • A.E. Dorofeev Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • Yu.G. Kuzenko Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2308-2097.54.3.2020.211740

Keywords:

fecal microbiota transplantation, intestinal dysbiosis, superdonors, review

Abstract

Fecal microbiota transplantation (FMT) is a highly effective therapeutic procedure for treating recurrent Clostridium difficile infection. However, the effectiveness of the FMT for the treatment of other chronic diseases associated with intestinal dysbiosis, until recently, remained very low and very variable. A number of studies conducted in recent years have suggested that the success of the FMT is largely dependent on the microbial diversity and composition of the donor stool, which has led to the concept of the existence of FMT superdonors, which are considered individuals whose FMT is accompanied by a high efficiency. The review presents some of the results of the FMT with the involvement of superdonors, describes the possible mechanisms and factors affecting the success of the FMT. It is concluded that the high diversity of the gut microbiota, especially in the donor, seems to be the best predictor of the patient’s response to the FMT. It is assumed that the identification and subsequent characterization of superdonor intestinal microbiomes will improve our understanding of the microbial component of chronic diseases and will allow the use of the FMT in a more targeted manner in the future.

Downloads

Download data is not yet available.

References

Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214. doi:10.1038/nature11234.

Goodrich JK, Waters JL, Poole AC, et al. Human genetics shape the gut microbiome. Cell. 2014;159(4):789-799. doi:10.1016/j.cell.2014.09.053.

Hall AB, Tolonen AC, Xavier RJ. Human genetic variation and the gut microbiome in disease. Nat Rev Genet. 2017;18(11):690-699. doi:10.1038/nrg.2017.63.

Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635-1638. doi:10.1126/science.1110591.

Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med. 2016;8(1):51. doi:10.1186/s13073-016-0307-y.

Kootte RS, Levin E, Salojärvi J, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017;26(4):611-619.e6. doi:10.1016/j.cmet.2017.09.008.

Lopez-Siles M, Martinez-Medina M, Abellà C, et al. Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease. Appl Environ Microbiol. 2015;81(21):7582-7592. doi:10.1128/AEM.02006-15.

Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-6.e7. doi:10.1053/j.gastro.2012.06.031.

Wilson BC, Vatanen T, Cutfield WS, O'Sullivan JM. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front Cell Infect Microbiol. 2019;9:2. doi:10.3389/fcimb.2019.00002.

Kelly CR, Kahn S, Kashyap P, et al. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015;149(1):223-237. doi:10.1053/j.gastro.2015.05.008.

Khanna S. Microbiota Replacement Therapies: Innovation in Gastrointestinal Care. Clin Pharmacol Ther. 2018;103(1):102-111. doi:10.1002/cpt.923.

Vermeire S, Joossens M, Verbeke K, et al. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4):387-394. doi:10.1093/ecco-jcc/jjv203.

Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-580. doi:10.1136/gutjnl-2016-313017.

Kump P, Wurm P, Gröchenig HP, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther. 2018;47(1):67-77. doi:10.1111/apt.14387.

de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes. 2017;8(3):253-267. doi:10.1080/19490976.2017.1293224.

Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835-843. doi:10.1111/apt.13144.

Kao D, Roach B, Silva M, et al. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017;318(20):1985-1993. doi:10.1001/jama.2017.17077.

Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500-508. doi:10.1038/ajg.2013.59.

Lee CH, Belanger JE, Kassam Z, et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis. 2014;33(8):1425-1428. doi:10.1007/s10096-014-2088-9.

Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479-493. doi:10.1111/apt.14201.

Kellingray L, Gall GL, Defernez M, Beales ILP, Franslem-Elumogo N, Narbad A. Microbial taxonomic and metabolic alterations during faecal microbiota transplantation to treat Clostridium difficile infection. J Infect. 2018;77(2):107-118. doi:10.1016/j.jinf.2018.04.012.

Osman, M, Stoltzner, Z, O'Brien, K, et al. Donor Efficacy in Fecal Microbiota Transplantation for Recurrent Clostridium difficile: Evidence From a 1,999-Patient Cohort. Open Forum Infect Dis. 2016;3(Suppl 1):841. doi:10.1093/ofid/ofw194.48.

Aroniadis, OC, Brandt LJ, Oneto C, et al. A double-blind, randomized, placebo-controlled trial of fecal microbiota transplantation capsules (FMTC) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Gastroenterology. 2018;154(6 Suppl 1):S154-S155. doi: 10.1016/S0016-5085(18)30932-6.

Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46(3):213-224. doi:10.1111/apt.14173.

Ding C, Fan W, Gu L, et al. Outcomes and prognostic factors of fecal microbiota transplantation in patients with slow transit constipation: results from a prospective study with long-term follow-up. Gastroenterol Rep (Oxf). 2018;6(2):101-107. doi:10.1093/gastro/gox036.

Fuentes S, Rossen NG, van der Spek MJ, et al. Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. ISME J. 2017;11(8):1877-1889. doi:10.1038/ismej.2017.44.

Goyal A, Yeh A, Bush BR, et al. Safety, Clinical Response, and Microbiome Findings Following Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(2):410-421. doi:10.1093/ibd/izx035.

Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-2115. doi:10.1136/gutjnl-2018-316434.

Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24. doi:10.1016/S2468-1253(17)30338-2.

Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149(1):102-109.e6. doi:10.1053/j.gastro.2015.04.001.

Conceição-Neto N, Deboutte W, Dierckx T, et al. Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC. Gut. 2018;67(8):1558-1559. doi:10.1136/gutjnl-2017-315281.

Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228. doi:10.1016/S0140-6736(17)30182-4.

Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017;11(10):1180-1199. doi:10.1093/ecco-jcc/jjx063.

Ponce-Alonso M, Garcia-Fernandez S, Aguilera L, et al. A new compatibility test for donor selection for faecal microbiota transplantation in ulcerative colitis. J Crohn's Colitis. 2017;11(Suppl 1):S480-S481. doi:10.1093/ecco-jcc/jjx002.903.

Rossen NG, Fuentes S, van der Spek MJ, et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015;149(1):110-118.e4. doi:10.1053/j.gastro.2015.03.045.

Kazerouni A, Wein LM. Exploring the Efficacy of Pooled Stools in Fecal Microbiota Transplantation for Microbiota-Associated Chronic Diseases. PLoS One. 2017;12(1):e0163956. doi:10.1371/journal.pone.0163956.

Mizuno S, Masaoka T, Naganuma M, et al. Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome. Digestion. 2017;96(1):29-38. doi:10.1159/000471919.

DeFilipp Z, Peled JU, Li S, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2018;2(7):745-753. doi:10.1182/bloodadvances.2018017731.

Li SS, Zhu A, Benes V, et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science. 2016;352(6285):586-589. doi:10.1126/science.aad8852.

Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016;165(6):1332-1345. doi:10.1016/j.cell.2016.05.041.

Smillie CS, Sauk J, Gevers D, et al. Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. Cell Host Microbe. 2018;23(2):229-240.e5. doi:10.1016/j.chom.2018.01.003.

Nishino K, Nishida A, Inoue R, et al. Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. J Gastroenterol. 2018;53(1):95-106. doi:10.1007/s00535-017-1384-4.

Kumar R, Yi N, Zhi D, et al. Identification of donor microbe species that colonize and persist long term in the recipient after fecal transplant for recurrent Clostridium difficile. NPJ Biofilms Microbiomes. 2017;3:12. doi:10.1038/s41522-017-0020-7.

Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15(1):73. doi:10.1186/s12967-017-1175-y.

David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-563. doi:10.1038/nature12820.

Thompson S, Guetterman H, Taylor A, et al. Dietary Predictors of Fecal Microbiota Transplantation Success. J Acad Nutr Diet. 2016;116(9 Suppl):А76. doi:10.1016/j.jand.2016.06.267.

Holvoet T, Joossens M, Boelens J, et al. Fecal Microbiota Transplantation in Irritable Bowel Syndrome with Predominant Abdominal Bloating: Results from a Double Blind, Placebo-Controlled Clinical Trial. Gastroenterology. 2018;154(6 Suppl 1):S130. doi:10.1016/S0016-5085(18)30860-6.

Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology. 2017;152(4):799-811.e7. doi:10.1053/j.gastro.2016.11.010.

Downloads

Published

2021-09-06

How to Cite

Tkach, S., Dorofeev, A., & Kuzenko, Y. (2021). The concept of superdonor and other possible factors for the effectiveness of fecal microbiota transplantation. GASTROENTEROLOGY, 54(3), 202–209. https://doi.org/10.22141/2308-2097.54.3.2020.211740

Issue

Vol. 54 No. 3 (2020)

Section

Reviews and Lections

License

Copyright (c) 2020 S.M. Tkach, A.E. Dorofeev, Yu.G. Kuzenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.